{
    "id": 26644,
    "fullName": "RAF1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RAF1 positive indicates the presence of the RAF1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5894,
        "geneSymbol": "RAF1",
        "terms": [
            "RAF1",
            "c-Raf",
            "CMD1NN",
            "CRAF",
            "NS5",
            "Raf-1"
        ]
    },
    "variant": "positive",
    "createDate": "06/07/2017",
    "updateDate": "07/12/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 375,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical study, the RAF1 antisense oligonucleotide ISIS 13650 inhibited Raf1 expression and cell growth in a human ovarian cancer cell line (PMID: 11742498).",
            "molecularProfile": {
                "id": 27911,
                "profileName": "RAF1 positive"
            },
            "therapy": {
                "id": 1025,
                "therapyName": "ISIS-13650",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 161,
                    "pubMedId": 11742498,
                    "title": "Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11742498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11123,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line co-expressing RAF1 and a BRAF mutation demonstrated inhibition of downstream Mapk1 signaling when treated with AZ628 (J Clin Oncol 35, 2017 (suppl; abstr e23154)).",
            "molecularProfile": {
                "id": 27912,
                "profileName": "BRAF mut RAF1 pos"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9096,
                    "pubMedId": null,
                    "title": "Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer",
                    "url": "http://abstracts.asco.org/199/AbstView_199_191661.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27911,
            "profileName": "RAF1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27912,
            "profileName": "BRAF mut RAF1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}